Once-weekly subcutaneous tirzepatide may not raise risk for depression compared with placebo, according to a post hoc analysis of the SURMOUNT trials. As Healio previously reported, in January the FDA ...

Popular GLP-1 and GIP medications, such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro) and liraglutide (Saxenda) ...

An Australian-led study suggests dietary intake and nutrition are being ignored in global studies of GLP-1s, which could result in malnutrition, even scurvy.

Six pharmaceutical companies have applied to make a generic version of semaglutide, and competition will continue to heat up ...

Patient leaflets on weight-loss injections state that gallstones are a "common" side effect, and in medical trials the injections also sometimes led to inflammation of the gallbladder. For example in ...

More than 4,400 lawsuits have been filed since millions of Americans embraced GLP-1 drugs like Ozempic, Wegovy and Mounjaro ...

Background: Remote patient monitoring (RPM) offers a potential solution to manage the increasing prevalence of chronic conditions challenges in healthcare systems worldwide, but its economic ...

By Mariam Sunny Jan 13 (Reuters) - The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, ...

The request applies to GLP-1 RAs approved for obesity, including Novo Nordisk’s Wegovy and Saxenda and Eli Lilly’s Zepbound.

Background: Structured medication reviews (SMRs) are an essential component of medication optimization, especially for patients with multimorbidity and polypharmacy. However, the process remains ...

Objectives This review aimed to investigate the relationship between staff experience and patient health and experience outcomes in hospital inpatient settings. Design Systematic review of reviews.